Valuing Biotech Companies

In: Business and Management

Submitted By almasy99
Words 5247
Pages 21
FORENSIC ACCOUNTING SPECIAL INTEREST GROUP VALUING A BIOTECHNOLOGY COMPANY
DAVID RANDERSON ACUITY TECHNOLOGY MANAGEMENT PTY LTD Melbourne, May 2001

1.

Valuation Methodologies

Techniques used for valuing intangible assets, of which intellectual property (IP) is one form, may be put into three main categories1: 1. Cost Based; 2. Market Based; and 3. Revenue Based. Biotechnology companies, because their main assets are generally IP, have values that are invariably determined by their intangible assets. The valuation of a mature company tends to follow a methodology that draws heavily on its historical income, either by performing a discounted cash flow of future earnings the confidence in which derives from past activity, or capitalisation of maintainable earnings. Another technique considers the orderly realisation of assets. As most biotechnology companies have no historical revenues and the tangible assets are not representative of a company’s real value, these methods are seldom applicable. Conceptually, the value of a company is the sum of its assets value. However, accounting practices allow companies to reflect only the tangible part of their assets. Obviously, high valuations of companies that are in negative cash flow and with minimal tangible assets is causing concern to the taxation office (as demonstrated by their stance on core technology valuations in R&D syndicates) and the Australian Securities and Investment Commission (ASIC).

1

Reilly RF, Schweihs RP, Valuing Intangible Assets, 1998.

Determining the worth of a research project or R&D based company by discounting free cash flow is more often than not of questionable worth since such methods often result in negative value. Biotechnology companies, as well as other high technology companies, trade on stock exchanges with considerable value. In addition, these companies raise capital,…...

Similar Documents

Biotech Business Plan

...INCYTE : BIOTECH FEST EVENT : BIOTECH BUSINESS PLAN INDIVIDUAL ENTRY : PROPOSAL : An R&D and production based organisation specialized in tissue culture and stem cell technology , skin and epidermal tissue culture and reintegration, cell-tissue-organ banking, cultivation of tissues which are compatible according to individual requirements. The venture will also have a humanitarian aspect of extending help to patients looking for organ replacement, burn victims in need of skin for skin grafting. The venture will have three intertwined multiple wings. An R& D wing to develop and improve on existing techniques, different production wings to execute the techniques, management groups to improve on marketing strategy advertising and spreding awareness. The main goal of this venture is to develop cell and tissue compatible with the recepient’s requirements and serve consumers with better availability of tissue and cell types . Easy availability will greatly increase survival rates, especially in case of burn victims who badly need skin grafting to survive. MARKETING STRATEGY : Purpose: Investments in Niche Biological Products and Services will lead to increases in export revenues of biologically-based products (apart from food products) with returns significantly above commodity levels based on global market-led and valued, research...

Words: 395 - Pages: 2

Valuing Biotech Companies

...FORENSIC ACCOUNTING SPECIAL INTEREST GROUP VALUING A BIOTECHNOLOGY COMPANY DAVID RANDERSON ACUITY TECHNOLOGY MANAGEMENT PTY LTD Melbourne, May 2001 1. Valuation Methodologies Techniques used for valuing intangible assets, of which intellectual property (IP) is one form, may be put into three main categories1: 1. Cost Based; 2. Market Based; and 3. Revenue Based. Biotechnology companies, because their main assets are generally IP, have values that are invariably determined by their intangible assets. The valuation of a mature company tends to follow a methodology that draws heavily on its historical income, either by performing a discounted cash flow of future earnings the confidence in which derives from past activity, or capitalisation of maintainable earnings. Another technique considers the orderly realisation of assets. As most biotechnology companies have no historical revenues and the tangible assets are not representative of a company’s real value, these methods are seldom applicable. Conceptually, the value of a company is the sum of its assets value. However, accounting practices allow companies to reflect only the tangible part of their assets. Obviously, high valuations of companies that are in negative cash flow and with minimal tangible assets is causing concern to the taxation office (as demonstrated by their stance on core technology valuations in R&D syndicates) and the Australian Securities and Investment Commission (ASIC). 1 Reilly RF...

Words: 5247 - Pages: 21

Valuing Stocks

...QUESTIONNAIRE ON VALUING STOCKS By: Bahae eddine Boussouf Nadezda Vovk 1) Common stock: a share of ownership in the corporation, which confers rights to any common dividends as well as rights to vote on election of directors, mergers, or other major events. Preferred stock: A class of ownership in a corporation that has a higher claim on the assets and earnings than common stock. Preferred stock generally has a dividend that must be paid out before dividends to common stockholders and the shares usually do not have voting rights. Preferred and common stocks are different in two key aspects. First, preferred stockholders have a greater claim to a company's assets and earnings. This is true during the good times when the company has excess cash and decides to distribute money in the form of dividends to its investors. In these instances when distributions are made, preferred stockholders must be paid before common stockholders. However, this claim is most important when the company must liquidate and pay all creditors and bondholders, common stockholders will not receive any money until after the preferred shareholders are paid out. Second, the dividends of preferred stocks are different from and generally greater than those of common stock. When you buy a preferred stock, you will have an idea of when to expect a dividend because they are paid at regular intervals. This is not necessarily the case for common stock, as the company's board of directors will decide...

Words: 1128 - Pages: 5

Valuing Oil & Gas

...Valuing Oil & Gas Reserves The oil and gas industry presents unpredictable challenges for finance professionals in valuing oil and gas assets. The upstream sector, exploration and production, is often considered the greatest investment risk amongst all three sectors. When estimating reserves quantities of recoverable reserves are classified as proved, probable, and possible. Proved reserves are divided up into four subsidiary categories; Proved developed producing reserves, proved developed non-producing reserves, proved being-pipe reserves, and proved undeveloped reserves. Completed wells that are currently being produced are considered proved developing producing reserves. These particular wells are regarded as energy sources estimated with reasonable certainty to be recoverable with existing equipment and under the existing operating conditions. Providing volume, pressure, and production information proved reserves are held as the most valuable of all. Proved developed non-producing reserves consist of proved reserves from wells which have been completed and identified but are not producing due to lack of minor completion problems. The upside to PDNP’s is these issues can be corrected. With the help of mechanical repair operations or initiating production the reserves can be produced. Expenditures may be required on the surface in order to get operations up and running, but no additional costs within the well is necessary. Proved behind-pipe reserves are those...

Words: 357 - Pages: 2

Biotech Internal Analysis

..., Profitability | No | Philosophy | Yes | Self-Concept | Yes | Public Image | No | Employees | No | FINANCIAL RATIOS ANALYSIS Cancer Genetics and Foundation Medicine were new public companies, so there were no history records for them before 2011. Figure 1: Current Ratio Table 8: Current Ratio Current Ratio | 2008 | 2009 | 2010 | 2011 | 2012 | Cancer Genetics | - | - | - | 0.76 | 0.18 | Foundation Medicine | - | - | - | 2.77 | 6.84 | Genomic Health | 4 | 3.97 | 4.53 | 4.93 | 5.14 | Myriad Genetics | 5.12 | 11.37 | 17.26 | 12.16 | 9.4 | Industry | 1.91 | 1.68 | 1.56 | 1.71 | 2.2 | Source: Mergent Comparison Report Myriad Genetics had the highest current ratios overall from 2008 to 2012. It was experiencing a strong upward trend from 2008 to 2010, then it started to drop. Myriad Genetics invested a large amount of current asset into its deferred long-term assets in 2011. The current ratios for Genomic Health and Foundation Medicine were all over the industry average as well. Genomic Health’s current ratio experienced a stable and slow rise from 2008 to 2012. Genomic Health’s capability to repay short-term obligations with current assets has increased. Cancer Genetics’ current ratio was under the industry average and below 1. The current ratio for Cancer Genetics in 2012 was lower than in 2011. Cancer Genetics had a significant increase on its current liabilities in 2012. Figure 2: Quick Ratio Table 9: Quick Ratio Quick Ratio | 2008 | 2009 |......

Words: 5057 - Pages: 21

Valuing Stocks

...Valuing Stocks 1. "As owners, what rights and advantages do shareholders obtain" (Cornett, Adair, & Nofsinger, 2014, p. 203)? They are able to participate in the economic growth of publicly traded firms without having to manage business entities directly. They have the right to residual cash flows of corporate profits and often receive some of these cash flows through dividends. In addition, shareholders vote on the members for board of directors and other proposals for the company. Shareholder capital losses are capped in that they can only lose their initial investment. Stocks are very liquid and investors can enjoy this liquidity in both their entrance into the stock market and their exit from it. 2. "Why might the Standard and Poor's 500 Index be a better measure of stock market performance than the Dow Jones Industrial Average" (Cornett, Adair, & Nofsinger, 2014)? The S&P 500 is a broad market index that includes stocks of the 500 largest US firms from ten sectors of the economy. It captures 80% of the overall stock market capitalization and is a good proxy for what is occurring in the overall stock market. 3. "What are the differences between common stock and preferred stock" (Cornett, Adair, & Nofsinger, 2014, p. 203)? Common stock dividends change over time, hopefully increasing in the long-term. Preferred stock pays a constant dividend. Preferred stockholders have higher precedence for payment in the event of firm...

Words: 528 - Pages: 3

Walmart Valuing

...VALUING WAL-MART-2010 Contents: 1. Background of Wal-Mart stores, Inc. 2. Valuing approach 3.1 Dividend Discount model 3.2 Capital asset pricing model 3.3 The Price/Earning multiple approach 3. Recommendation 1. Background Wal-Mart stores, Inc. Wal-Mart was the world’s largest retailer, operating more than 8,400 stores worldwide. Wal-Mart’s strategy was to provide a broad assortment of quality merchandise and services at ”everyday low prices”. In general merchandise area, Wal-Mart’s competitors included Sears and Target; In terms of specialty retailers, its competitors included Gap and Limited; Department store competitors included Dillard’s and Macy’s; Grocery store competitors included Safeway and Kroger; The major membership-only warehouse competitor was Costco Wholesale. 2. Valuing approach In this case, I will use three different methods, including the capital asset pricing model (CAPM), the dividend discount model, and the price/earnings multiples, to value the War-Mart, Inc. and to determine whether this company was fairly valued. 3.1 Dividend Discount model * Method introduction According to the dividend discount model(DDM), the current stock price of Wal-Mart represents the present value of all expected future dividends, discounted at an investor’s required rate of return. Under this approach, a share is valued by forecasting dividends in perpetuity. Then, P0 = D1/(Ke – g) * Source...

Words: 817 - Pages: 4

Biotech

...).  Large-cap biotech: We don’t believe that a strict assessment of P/E multiples accurately addresses the nuances of the sector (2014e – Biotech: 22x vs. S&P 500: 15x). In our view, large caps are poised for an inflection point in revenue growth over the next two years, driven by significant drug launches in major therapeutic categories. Some of these include Gilead’s Sovaldi in hep C, Biogen’s Tecfidera in MS, Celgene’s myeloma franchise and Vertex’s CF franchise. Importantly, there are many innovative products in SMid-cap biotech that are also in launch mode.  SMid-cap biotech: SMid-cap performance is primarily driven by clinical/ regulatory catalysts which should still be the case in 2014. That said, there are many high-profile drug launches in the SMid-cap space such as Pharmacyclics’ Imbruvica, Biomarin’s Vimizim, Agerion’s Juxtapid and NPS Pharma’s orphan drug franchise. The innovation and scarcity value across SMid-cap biotech makes the group strategically attractive and while it’s difficult to predict, we suspect that M&A will remain a key theme in the group. This should be particularly true for companies in “hot” therapeutic categories and/or with de-risked platform technologies.  2014 Sector tailwinds: The regulatory environment remains stable with only a few surprises in 2013 and the pricing/reimbursement overhang in the EU appears to have abated. In 2014, we expect to hear from more commercial biotechs on the emerging markets opportunity, which is unaccounted......

Words: 13041 - Pages: 53

Biotech

...Biotechnology is a relatively new field of business. Biotechnology deals with the use, production of products derived from a biological source. There are several sectors that comprise the industry of biotechnology. The business and technology each sector possesses has both unique characteristics and similar characteristics. Examining five of these sectors: Vertically integrated biotechnology company, biotechnology start-up company, Contract Research/Manufacturing Organizations (CRO/CMO), Fuel biotechnology and Agri-biotechnology we can see what the unique properties each of these sectors have and what they share with each other. Vertically Integrated Biotechnology Company Vertical integration is the replacement of transactions in the marketplace with internal transactions within the company. Vertical integration is the result of mergers acquisitions of other companies that once supplied the parent company. It allows the company to control the economy of its products. The use of this business model has led to many advantages and disadvantages within the biotechnology industry. Vertical integration of biotech companies has offered many advantages to the growth of not only the business but also the growth of the technology offered by the company. However, growth through integration can also have many disadvantages. By examining both we can see how vertical integration plays a part in the growth of a biotechnology company. The vertical integration model has been...

Words: 1107 - Pages: 5

Valuing Stocks

..."As owners, what rights and advantages do shareholders obtain" (Cornett, Adair, & Nofsinger, 2014, p. 203)? "Why might the Standard and Poor's 500 Index be a better measure of stock market performance than the Dow Jones Industrial Average" (Cornett, Adair, & Nofsinger, 2014)? "What are the differences between common stock and preferred stock" (Cornett, Adair, & Nofsinger, 2014, p. 203)? "On March 14, 2013, the Dow Jones Industrial Average set a new high. The index closed at 14,539.14, which was up 83.86 points from the previous day's close of 14.455.28. What was the return (in percent to four decimal places) of the stock market for March 14, 2013" (Cornett, Adair, & Nofsinger, 2014)? "At your brokerage firm, it costs $9.50 per stock trade. How much money do you need to buy 300 shares of Time Warner, Inc. (TWX), which trades at $22.62" (Cornett, Adair, & Nofsinger, 2014)? "Financial analysts forecast Safeco Corporation (SAF) growth for the future to be a constant 10 percent. Safeco's recent dividend was $1.20. What is the value of Safeco stock when the required return is 12 percent" (Cornett, Adair, & Nofsinger, 2014, p. 205)? "A preferred stock from Duquesne Light Company (DQUPRA) pays $2.10 in annual dividends. If the required return on the preferred stock is 5.4 percent, what is the value of the stock" (Cornett, Adair, & Nofsinger, 2014, p. 204)? "Ultra Petroleum (UPL) has earnings per share of $1.56 and a P/E ratio of 32.48. What is the stock price" (Cornett, Adair...

Words: 261 - Pages: 2

Valuing Bonds

...Valuing Bonds 1. "What does a call provision [call feature] allow [bond] issuers to do, and why would they do it" (Cornett, Adair, & Nofsinger, 2014)? “A call provision on a bond issue allows the issuer to pay off the bond debt early at a cost of the principal plus any call premium. Most of the time a bond issuer is called, it is because interest rates have substantially declined in the economy. The issuer calls the existing bonds and issues new bonds at the lower interest rate. This reduces the interest payments the issuer must pay each year” (Cornett, Adair, & Nofsinger, 2014). 2. "Provide the definitions of a discount bond and premium bond. Give examples" (Cornett, Adair, & Nofsinger, 2014, p. 178). “A discount bond is simply a bond that is selling below its par value. It would be quoted at a price that is less than 100 percent of par, like 99.05. A premium bond is a bond selling above its par value. Its price will be quoted as over 100 percent of par value, like 101.15. A bond becomes a discount bond when market interest rates rise above the bond’s coupon rate. A bond becomes a premium bond when market interest rates fall below the bond’s coupon rate” (Cornett, Adair, & Nofsinger, 2014, p. 178). 3. "Describe the differences in interest payments and bond prices between a 5 percent coupon bond and a zero coupon bond" (Cornett, Adair, & Nofsinger, 2014, p. 178). “The 5 percent coupon bond pays annual...

Words: 565 - Pages: 3

Valuing Coca Cola Stock

...Valuing of Coca Cola Stock and Analysis Andrew Burgoyne, James Desimone, Bailey Fowble, Hewei Huang, Ryan Leist, Maria Sandoval University of South Florida FIN 4414 Abstract Taking the role as Jessie Jones, we will analyze whether to recommend the Coca Cola stock to potential clients or current clients that do not have it in their portfolio. By using the Capital Asset Price Model (CAPM), Dividends Discount Model (DDM) and the Price/Earnings (P/E) ratio we will come to a conclusion. Background The Coca Cola Company, which is based out of Atlanta, Georgia, is a leader in the global soft drink market. It owns subsidiaries in over 195 countries around the world but has always remained local. According to the most recent Value Line (1997) report, revenues and profits were expected to continue to grow for the rest of the year but still be weaker than the current year. They forecasted that Coca Cola would meet their goal of increasing profits by 15% each year for the next 3-5 years due to the expanding soft drink market. Jessie Jones, an Investment Advisor with a major brokerage firm, wondered whether she should recommend the Coca Cola stock to any of her potential clients or current clients that did not already have it in their portfolios. Jessie noticed that the current price of Coke slipped to $58 per share with a price/earnings ratio of 35x and dividends yield of 1%. The methodologies used to value the stock of Coca Cola are: CAPM, DDM and P/E ratio...

Words: 1225 - Pages: 5

Finance Course - Hypothetical Biotech Case

...Table of Contents I. Early/mid stage biotech funding environment at a glance II. “Regenerate Biomedical” (fictional biotech company) overview a. Company milestones, stakeholders, funding to date b. Preliminary testing results for DRX c. Clinical Trials and funding needs for DRX d. Overview of Phase I Results for DRX e. Probability DRX clears phase II III. Market Overview - Hair Therapy Industry a. Market and competitive landscape b. DRX competitive advantage c. DRX Sales Forecast (three scenarios) d. Analyst Assumptions IV. Risk Profile for early/mid stage biotech companies a. Assumptions- Beta, Cost of Capital, WACC V. Overview Regenerate Biomedical funding options for DRX a. Initial Public Offering (IPO) b. Private Equity (PE) c. Big pharmaceutical company a. “Aderans” preliminary acquisition offer d. Venture Capital b. “Bio Venture” preliminary deal terms VI. Results and Conclusion a. Strategy 1 b. Strategy 2 c. Strategy 3 I. Early/mid stage biotech funding environment at a glance Biotechnology is typically defined as any science that harnesses cellular and bimolecular substances to develop new technology, drugs and products. Biotechnology has multiple applications - food alteration, genetic research, environment and energy, and human and animal health products, to name a few. Over the years, the biotech industry has produced some of the world’s greatest advances...

Words: 4652 - Pages: 19

Biotech

...EITF Issue No. 08-9 Appendix 08-9A EXAMPLES The following examples are provided to illustrate the application of the various views under Issue 2 of Issue Summary No. 1, Supplement No. 1. Fact Pattern - Biotech License and R&D Contract Biotech Company (Biotech) enters into an agreement with Pharmaceutical Company (Pharma) on January 1, 20X1. The agreement includes Biotech (a) licensing certain intellectual property rights to Pharma and (b) providing research and development (R&D) services to Pharma with the objective of developing a viable drug candidate and receiving U.S. Food and Drug Administration (FDA) approval of the drug candidate. Arrangement consideration is as follows: • • Biotech receives $5 million in licensing fees upon signing the agreement Biotech receives $250,000 per year for each full-time equivalent (FTE) that performs R&D activities • Milestone Events: 1. Biotech receives $2 million upon identification of a viable drug candidate 2. Biotech receives $3 million upon successful Phase II clinical trial completion 3. Biotech receives $5 million upon FDA approval. The license and FTE fees are comparable to rates charged by Biotech in other arrangements and are also considered comparable to rates charged by Biotech's competitors and contract research organizations. None of these payments, once received, are refundable, even if FDA approval is never received. In addition, while Biotech must perform on a best-efforts basis, it is not obligated to...

Words: 1563 - Pages: 7

Biotech

...Summer Project Report Study of MDA (malondialdehyde) as abiotic stress marker in CSV-17 variety of Sorghum bicolor. Submitted in partial fullfilement of the requirement for B.Tech. Biotechnology Semester VII AMITY INSTITUTE OF BIOTECHNOLOGY AMITY UNIVERSITY RAJASTHAN JAIPUR 2011 Supervised by: Dr Ajit Kumar Sr. Research Officer S.P. Institute of Biotechnology, Jaipur Submitted by: Ravi Pareek DECLARATION I hereby declare that the project report entitled “Study of MDA (malondialdehyde) as abiotic stress marker in CSV-17 variety of Sorghum bicolor” is a record of the work compiled by me under the supervision and guidance of Dr. Ajit Kumar, S.P. Institute of Biotechnology, Jaipur as a part of my 45 days summer training. Ravi Pareek (B.TECH-BIOTECHNOLOGY) (AUR0821094) ACKNOWLEDGEMENT First of all with due regard to my respective god with whose kindness and blessing we could be able to accomplish the task of training. Mr. Sourabh Pareek, for his kind permission to allow me to undergo my major project at S. P. Institute of Biotechnology, Jaipur. I am overwhelmed with rejoice to take this opportunity to evince my profound sense of reverence and gratitude to my esteemed supervisor respective Dr. Ajit Kumar, for giving his regular advice and excellent suggestion which have helped us for completing the study. His regular assistance and guidance really helped me to bring formidable task in successful manner. Sincere thanks to Dr. Sonali Jana and Dr. Neha Upreti for their...

Words: 12095 - Pages: 49